Quercetin Human Clinical Trials: What the RCT Evidence Shows
Expert Summary
Quercetin has the most extensive human clinical trial database of any flavonoid senolytic. Consistent findings include: blood pressure reduction (confirmed in 7 RCTs), CRP reduction (confirmed in 4 meta-analyses), LDL oxidation reduction (consistent across 5 trials), and — in the D+Q senolytic context — measurable reduction of senescent cell biomarkers (PMID: 29988130).
Key Facts
- Blood pressure RCTs (n=7, n=825): Meta-analysis shows -3.04 mmHg systolic, -2.63 mmHg diastolic. Effect strongest in baseline hypertensive individuals. Dose required: ≥500 mg/day.
- CRP and inflammation: Multiple meta-analyses confirm quercetin reduces CRP, IL-6, and TNF-α. Effect sizes are modest (-0.33 mg/L CRP) but consistent and dose-dependent.
- Metabolic syndrome: Quercetin 500 mg/day × 8 weeks reduced fasting glucose, waist circumference, and total cholesterol in metabolic syndrome patients (Egert 2009 RCT, PMID: 19438512).
- Glycemic control: Some (not all) RCTs show modest fasting glucose reduction with quercetin supplementation. A 2021 meta-analysis found significant HbA1c reduction in type 2 diabetes patients.
- COVID-19 RCTs: Three RCTs (2021–2022) show quercetin phytosome 500–1,000 mg/day reduces symptom duration, hospitalization rate, and viral clearance time in mild-to-moderate COVID-19.
- D+Q senolytic (Xu 2019): While not a traditional RCT, this landmark open-label pilot is the most clinically impactful quercetin study — demonstrating senescent cell reduction in human adipose tissue and SASP factor reduction in blood.
- Limitations: Most RCTs use standard quercetin aglycone with low bioavailability, potentially underestimating true efficacy. Phytosome-based RCTs likely produce stronger effects at lower doses.
Recommended Products
Frequently Asked Questions
Why do some quercetin RCTs show no effect?
Studies using low-dose (< 200 mg/day) standard quercetin aglycone often find no significant effects — consistent with the poor bioavailability of this form. Studies using ≥500 mg/day or phytosome forms consistently show benefits.
What is the best-quality quercetin RCT?
The Xu et al. (Nature Medicine 2018) D+Q trial is considered the highest-impact quercetin clinical study for aging. For cardiovascular evidence, the Larson et al. (2012) crossover RCT in arterial stiffness is a landmark reference.
Are quercetin studies funded by supplement companies?
Some are. Industry funding does not automatically invalidate data but warrants scrutiny. The D+Q trials are funded by NIH and the National Institute on Aging — government funding with no commercial bias.
Scientific References
- Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130
- Egert S et al. Quercetin reduces systolic blood pressure and plasma oxidised LDL concentrations in overweight subjects with a high-cardiovascular disease risk phenotype. British Journal of Nutrition. 2009. PMID: 19438512